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Abstract
Background: Microarray chips are being rapidly deployed as a major tool in genomic research.
To date most of the analysis of the enormous amount of information provided on these chips has
relied on clustering techniques and other standard statistical procedures. These methods,
particularly with regard to cancer patient prognosis, have generally been inadequate in providing
the reduced gene subsets required for perfect classification.
Results: Networks trained on microarray data from DLBCL lymphoma patients have, for the first
time, been able to predict the long-term survival of individual patients with 100% accuracy. Other
networks were able to distinguish DLBCL lymphoma donors from other donors, including donors
with other lymphomas, with 99% accuracy. Differentiating the trained network can narrow the
gene profile to less than three dozen genes for each classification.
Conclusions: Here we show that artificial neural networks are a superior tool for digesting
microarray data both with regard to making distinctions based on the data and with regard to
providing very specific reference as to which genes were most important in making the correct
distinction in each case.
Background
Alizadeh et al. [1] did a large scale, long-term study of dif-
fuse large B-cell lymphoma (DLBCL), using microarray
data chips. By doing cluster analysis on this data, they
were able to diagnose 96 donors with an accuracy of 93%
for this specific lymphoma; they were not able to predict
which individual patients would survive to the end of the
long-term study. The International Prognostic Index for
this disease was incorrect for 30% of these patients.
Cluster analysis, together with other statistical methods
for identifying and correlating minimal gene lists with
outcome, have become established as the primary tools
for the analysis of microarray data in cancer studies. We
wished to test a different approach, ANN.
These two approaches to the analysis of microarray data
differ substantially in their mode of operation. In the first
examination of the data, clustering, as applied in numer-
ous recent cancer studies, is an unsupervised mapping of
the input data examples based on the overall pairwise
similarity of those examples to each other (here, similarity
with respect to the expression levels of thousands of
genes); the method is unsupervised in that no
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information of the desired outcome is provided. Subse-
quent analysis of the clusters in these studies generally at-
tempts to reduce the gene set to the subset of genes that
are most informative for the problem at hand. This step is
a supervised step since there is an explicit effort to find
correlations in the pattern of gene expression that match
the classification one is attempting to make among the in-
put examples (see Discussion for specific examples). The
input for this supervised step is the product of an unsuper-
vised step. As this subselection is not routinely subjected
to independent test using input examples originally with-
held from the subselection process, it is generally not pos-
sible to judge how specifically the subselection choices
relate to this specific set of examples as opposed to the
general population of potential examples. To the extent
that the gene set employed is much larger than the gene
set that really determines the classification, it is possible
that much of the clustering result will be based on irrele-
vant similarities.
On the other hand, backpropagation neural networks are
a supervised learning method that has an excellent repu-
tation for classification problems. During the training
phase, the ANN are supplied with both the input data and
the answer and are specifically tasked to make the classifi-
cation of interest, given a training set of examples from all
classes. That is, the ANN are constantly checking to see if
they have gotten the 'correct' answer, the answer being the
actual classification not just the overall similarity of
inputs.
Networks accomplish this by continually adjusting their
internal weighted connections to reduce the observed er-
ror in matching input to output. When the network has
achieved a solution that correctly identifies all training ex-
amples, the weights are fixed; it is then tested on input ex-
amples that were not part of the training set to see if the
solution is a general one. It is only in this independent test
that the quality of the network is judged.
Investigators are not limited to a single network. It is fea-
sible to train a series of networks using, say, 90% of the ex-
amples for training and holding back 10% for testing. A
different 10 % can be tested in a second network and so
on. In this way, with the training of ten networks, each in-
put can be found in a test set one time and can, therefore,
be independently evaluated. The data presented below,
with the exception of a few cases, are the output of ten
slightly different trained networks, operating in test mode,
which collectively evaluate the entire donor pool. This
'round-robin' procedure was employed, in duplicate, in
every trial described throughout this work. The fact that
one ends up with 10 networks is not an impediment to
analysis since any future examples could be submitted to
all 10 networks for evaluation, with a majority poll decid-
ing the classification. That is, six networks in agreement
on a particular input datum would determine the classifi-
cation of that input. These networks are, of course, likely
to be very similar in that their training sets differ only
slightly.
A second major advantage of backpropagation networks
follows from the first. Not only are neural networks
trained to the specific question, rather than a loose deriv-
ative of that question, and tested for generality, but they
can also be asked for a quantitative assessment of how
they got the correct answer. Numerical partial differentia-
tion of the network with respect to a given test input ex-
ample [2,3] allows one to see the network's evaluation of
the relative impact of each gene in arriving at the correct
answer for this particular input. Cluster analysis, includ-
ing the statistical correlations, has no corresponding high-
ly focused sight for targeting specific similarities as
opposed to non-specific similarities. To the extent that
this is true, neural networks should be able to identify rel-
atively small gene subsets which will significantly outper-
form the initial gene sets in classification and which will
also significantly outperform the gene subsets suggested
by cluster analysis.
Results
Determining patient prognosis from microarray data
Cluster analysis [1,4] had shown that the 4026 gene ex-
pression panels for 40 DLBCL patients contained some in-
formation relevant to the question of prognosis but these
authors did not make an attempt to provide survival pre-
dictions for individual patients.
We wished to see if the neural network strategy, of train,
test, differentiate, retrain on the reduced gene set, and
retest, could produce any useful result with respect to
prognosis on an individual basis. The approach would be:
[1] use the entire gene set without preprocessing to train a
network, testing to confirm that it had at least a good fit to
the problem and, [2] use the network's definition of the
problem, by differentiating the network, to focus on those
genes most essential to the classification. These genes
would then form the basis for training new networks with
hopefully improved performance. Over 130 networks
were trained for this study. Figure 1 shows a work flow
schematic for this study. Table 1 provides a summary
overview of the data, including data not shown.
Initially a network was trained to accept microarray data
on the complete panel of 4026 genes from 40 patients.
This network had 12078 input neurons with a semi-quan-
titative assessment of each gene, 100 middle-layer neu-
rons, and a single output neuron. The networks were
originally designed with 3 input bits per datum: one for
sign,'-' = 1, and 2 for quantitative degree of signal with 00BMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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being 0 to 0.5, 01 being >0.5 to 1.0, 10 being >1.0 to 2.0,
and 11 being >2.0. Thus '011' would indicate a particular
gene whose expression, relative to control, was increased
at a magnitude >2. The training set included 30 donors,
with 10 additional donors being held back as test data.
The network was trained by processing 12 iterations of the
complete training set. The test set, drawn from a mixture
of survivors and non-survivors, was then run. The entire
process was then repeated with a different choice of test
data each time. In this round-robin fashion, all donors
serve as test data for one of the networks, and each train-
ing set is necessarily slightly different. A round robin series
of 4 networks was generated. Data underlying Figure 5 of
the earlier report http://llmpp.nih.gov/lymphoma/da-
ta.shtml were used for training. The networks were asked
to predict, based on the 4026 gene set, which of 40 DLBCL
patients would survive to the end of the study (longest
point = 10.8 yrs). Networks initially varied with from 1 to
3 errors on 10 test patients each, for a total of 31 of 40 pa-
tients correctly predicted (data not shown).1 However, a
trained neural network can be numerically differentiated
[2,3] to show the relative dependence of the output (clas-
sification) on each active input neuron within an input
vector. Briefly stated, the differentiation process involves
slightly perturbing the activation (down from 1.0 to 0.85)
of each active input neuron, one at a time, to note the spe-
cific change in the output value. In that there is one gene
for each active node, the largest change in the output
points to the most influential gene. We then trained qual-
itative networks, with 2 bits per gene, on the 4026 gene set
in order to differentiate them ('1 0' for expression greater
than, or equal to, the control, '0 1' for less than the con-
trol). The networks had 67 middle layer neurons. This
coding has the effect that there is an active neuron for each
gene in the set regardless of expression level and the total
number of active input neurons is constant from input to
input. By taking the top 25% of genes in each of 12 differ-
entiations and requiring agreement of at least 4 of 12 pa-
tients in choosing each gene, we obtained a set of 34
genes. (These cutoff criteria are necessarily arbitrary and
are only justified by subsequent proof that they produced
gene subsets having the desired information.) A round-
robin series of 10 networks, with 4 test donors each, pro-
duced a single error (DLCL0018) in survival predictions
when trained on these 34 genes (data not shown)1. The
second round-robin training with the same gene set pro-
duced no errors, correctly evaluating all 40 patients in a
series of 10 test sets (Table 2).
For a second study, we took 20 patients and held them in
reserve to model information from a "follow-up" study.
Twenty networks were trained, on the 34 gene set, using
the remaining 20 patients; each had 19 patients in the
training set and 1 in the test set. Collectively, these net-
works made no errors in the prognosis of 20 patients. The
data for the 20 reserve patients were then tested on all 20
trained networks to emulate follow-up data. Out of 400
individual scores, there were 5 errors distributed over 2
patients. A poll of the 20 networks, therefore, produced
Figure 1
Flow schematic for the prognostic studies. This diagram 
shows the work path of the networks developed for optimiz-
ing patient prognosis.BMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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Table 1: Summary of all data with web site designators
Network # Networks Trn/Tst # Genes # Correct False Positive Shown/NS
P1 4 30/10 4026 31/40 8 NS
P2D 4 30/10 4026 31/40 5 NS
P3 10 36/4 34 39/40 0 NS
P4 10 36/4 34 40/40 0 Table 2
P5 20 19/1 34 20/20 0 NS
/20 34 20/20 0 NS
P5 2 20/20 34 39/40 1 Comment
D1 10 9–86/10 4026 90/96 2 NS
D2D 1 86/10 4026 10/10 0 NS
D3 10 9–86/10 1–90/6 292 93/96 1 NS
D4 10 9–86/10 1–90/6 292 93/96 1 NS
D5 10 9–86/10 1–90/6 146 odd 93/96 1 NS
D6 10 9–86/10 1–90/6 146 even 95/96 1 Table 4
D7 10 9–86/10 1–90/6 146 even 95/96 1 NS
D8D 10 9–86/10 1–90/6 292 94/96 1 NS
D9D 3 86/10 146 even 95/96 1 NS
D10 10 9–86/10 1–90/6 19 94/96 1 Table 5
D11 11 9–42/4 2–41/5 19 43/46 1 NS
/50 19 49/50 0 NS
P1 indicates prognosis data first reference. D2D indicates diagnostic data used for differentiation, second diagnostic reference.
Table 2: Test results of ten networks trained on 34 genes to predict survival among 40 patients
DC NC DC NC
1.000000 0.956252 0.000000 0.189422
1.000000 0.958524 1.000000 0.983387
0.000000 0.030129 1.000000 0.966530
0.000000 0.051647 1.000000 0.972530
0.000000 0.015859 1.000000 0.986147
1.000000 0.960534 0.000000 0.025629
1.000000 0.959209 1.000000 0.934555
1.000000 0.988239 0.000000 0.153694
1.000000 0.883620 0.000000 0.058486
1.000000 0.983992 1.000000 0.985480
1.000000 0.828421 1.000000 0.949153
1.000000 0.527326 1.000000 0.956245
0.000000 0.046066 0.000000 0.147404
0.000000 0.025371 0.000000 0.025772
1.000000 0.987961 1.000000 0.782100
0.000000 0.145338 1.000000 0.977907
0.000000 0.130954 0.000000 0.223562
0.000000 0.148107 0.000000 0.039306
0.000000 0.020277 1.000000 0.982544
1.000000 0.956488 0.000000 0.025932
DC indicates the actual donor class, with 0.0 being negative. NC gives the network evaluation. The NC cutoff throughout this work is: ≥ 0.50 is 
taken as 1 and <0.50 is taken as 0. * marks the errorsBMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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no errors by a majority, correctly classifying all 20 mem-
bers of the follow-up group.(data not shown)
The 34 genes are given in Table 3. In 5 of 12 cases, the gene
chosen as most influential in determining the correct
prognosis was 18593, a tyrosine kinase receptor gene.
While this gene set may not be the absolute best possible,
it clearly does contain sufficient information for error-free
predictions on these patients. The identification of this
gene set will hopefully lead eventually to a better under-
standing of the interaction of these genes in this disease as
a result of future studies.
Diagnosing lymphoma from microarray data
The diagnosis of DLBCL lymphoma by biopsy is not triv-
ial. Even with gene expression data, clustering techniques
produced a misreading of 7 out of 96 donors [1], a result
unimproved in their hands by further analysis of reduced
gene panels. We wished to see if back propagation neural
networks could do better using the same data set. Figure 2
shows a work flow schematic for this study. This testing
over the whole donor set with 4026 genes produced 6 er-
rors in diagnosis (data not shown).
Thus, in the first round, ANN merely match cluster analy-
sis. In preparation for differentiation, a network was
trained with the same donor sets as the first network
above, but coded qualitatively. This network correctly
classified the 10 members of the test set (data not shown).
The 5 positive donors from the test set were each used, in
turn, to differentiate the network. In these cases, the first
criterion for selection was broad: the gene had to contrib-
ute at least 10% as much as the gene making the maxi-
mum contribution to the correct classification; the second
criterion was that 3 or more of the donors had to agree on
the selection. This produced a subset of 292 genes. The
number of genes referenced by a given donor under iden-
tical criteria ranged from 45 to 1448. Only 38% of the
genes overlapped the 670 gene subset identified by cluster
analysis. It was of interest to see if these genes were suffi-
cient for correct classification of the donors. Ten different
networks were trained with the 292 gene subset. Three
(OCI Ly1 and DLBCL0009 and tonsil) errors were pro-
duced over 96 donors in 2 separate series (data not
shown).
At this point, the neural networks were doing a much-im-
proved diagnosis; it remained to be seen if the gene set
could be further refined. The set of 292 genes was then
treated in two different ways: [1] it was arbitrarily split
into even and odd halves, with each half being used to
train ten new networks. [2] it was used whole to train ten
qualitative networks for further differentiation.
Twenty different networks were then trained using a 146
gene (odd or even numbered) subset of the 292 gene set
in 2 series of 10. The odd set again produced 3 errors (data
not shown). In the even set, a single error was made over
96 donors in ten different test sets, identifying the 'tonsil'
inlier in the earlier cluster analysis [1] as positive (Table
4). Ten additional networks were trained on the even set
with the same result (data not shown).
The differentiation of the networks from the 292 gene set
pointed to 8 genes. Given the high accuracy of the even
146 gene set, we also trained networks on this set for dif-
ferentiation. These pointed to 11 additional genes. In
these cases, only genes in the top 20% in influence chosen
in common by at least 25% of the differentiated examples
were considered. Networks trained on these 19 genes pro-
Table 3: 34 genes identified in prognostic series
14706 Unknown Hs. 180836 17856 Interferon alpha/beta receptor-2
21367 Unknown Hs. 134746 21653 Unknown Hs. 1510936
13601 Similar to high mobility group 15656 Unknown
20397 FBP1 = FUSE binding protein 1 14393 Unknown Hs. 29205
17901 *pre-pro-orphanin 16631 Adenosine kinase
13097 Unknown 13318 Unknown Hs. 122428
14560 Unknown Hs. 32533 18330 Topoisomerase II beta
13867 Unknown 14983 Unknown
15664 Unknown 17721 Id1 = Inhibitor of DNA binding 1
20490 Unknown Hs. 122407 16850 pM5 protein = homology to collagenase
13650 Unknown 20481 Unknown Hs. 37629
18252 myosin-IC 17398 receptor r-1BB ligand
16886 JAW1 14772 Unknown
18593 Receptor protein-tyrosine kinase 19280 BENE
20759 Unknown Hs. 33053 21603 Unknown Hs. 33431
17802 thymosin beta-4 19258 tre-2
17887 A-raf = c-raf-1 kinase 21091 Unknown Hs. 199250BMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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Figure 2
Flow schematic for the diagnostic studies. This diagram shows the work path of the networks developed for optimizing patient 
diagnosis.BMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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duced 2 errors over 96 donors in 10 test sets (Table 5). The
19 genes, using the designation from the initial report, are
given in Table 6.
We also wished to test this gene set in the context of a fol-
low-up study. For this purpose, we set aside 50 donors as
"follow-up" data, using the remaining 46 donors in the
usual training/testing round robin. Eleven networks were
trained, 9 with 42 training vectors and 4 test vectors and 2
with 41 training vectors and 5 test vectors. Collectively,
these produced 3 errors over 46 donors or 93% correct.
The follow-up donors were then tested on the 11 net-
works. A poll of these networks showed a majority vote
for 1 error or 98% correct.
Discussion
The rather remarkable conclusion of this analysis is that
there is sufficient information in a single gene expression
time point of less than 5 dozen genes to provide perfect
prognosis (out to ten years) and near-perfect diagnosis for
this set of donors. Furthermore, neural networks, through
a strategy of train and differentiate, bring that information
to the fore by progressively focusing on the genes within
the larger set which are most responsible for the correct
classifications, providing at once a reduction in the noise
level and specific donor profiles. This focus on the specific
classification problem led to a set of 34 genes for progno-
sis and a second set of 19 genes for diagnosis. These sets
are mutually exclusive. The gene subsets suggested by clus-
ter analysis [1] are not supersets of these sets; the 670 gene
Table 4: Test results of ten neural networks, trained on 146 genes to diagnose 96 donors for DLBCL lymphoma
DC NC DC NC DC NC
1 . 0 0 0 00 . 9 7 1 41 . 0 0 0 00 .9877 1.0000 0.9881
1 . 0 0 0 00 . 9 7 4 41 . 0 0 0 00 .9889 1.0000 0.9877
1 . 0 0 0 00 . 9 6 4 51 . 0 0 0 00 .9754 1.0000 0.9877
1 . 0 0 0 00 . 9 7 7 81 . 0 0 0 00 .9847 1.0000 0.9876
1 . 0 0 0 00 . 9 7 8 41 . 0 0 0 00 .9715 1.0000 0.9862
0 . 0 0 0 00 . 0 2 0 20 . 0 0 0 00 .0183 0.0000 0.0138
0 . 0 0 0 00 . 0 2 2 20 . 0 0 0 00 .0186 0.0000 0.0145
0.0000 0.9698* 0.0000 0.0176 0.0000 0.0153
0 . 0 0 0 00 . 3 1 6 20 . 0 0 0 00 .0182 0.0000 0.0140
0 . 0 0 0 00 . 0 1 7 00 . 0 0 0 00 .0205 0.0000 0.0155
1 . 0 0 0 00 . 9 8 2 01 . 0 0 0 00 .9870 1.0000 0.9849
1 . 0 0 0 00 . 9 8 1 71 . 0 0 0 00 .9849 1.0000 0.9839
1 . 0 0 0 00 . 9 8 2 11 . 0 0 0 00 .9790 1.0000 0.9858
1 . 0 0 0 00 . 9 8 0 31 . 0 0 0 00 .9859 1.0000 0.9849
1 . 0 0 0 00 . 9 6 1 11 . 0 0 0 00 .9811 1.0000 0.9841
0 . 0 0 0 00 . 0 1 2 70 . 0 0 0 00 .0276 0.0000 0.0217
0 . 0 0 0 00 . 0 4 1 50 . 0 0 0 00 .0435 0.0000 0.0221
0 . 0 0 0 00 . 0 1 0 90 . 0 0 0 00 .2255 0.0000 0.0213
0 . 0 0 0 00 . 0 1 1 50 . 0 0 0 00 .1417 0.0000 0.0216
0 . 0 0 0 00 . 0 1 1 50 . 0 0 0 00 .1463 0.0000 0.0218
1 . 0 0 0 00 . 9 8 5 71 . 0 0 0 00 .9703 1.0000 0.9953
1 . 0 0 0 00 . 9 8 5 01 . 0 0 0 00 .9765 1.0000 0.9953
1 . 0 0 0 00 . 9 8 7 71 . 0 0 0 00 .9752 1.0000 0.9953
1 . 0 0 0 00 . 9 4 3 61 . 0 0 0 00 .9742 1.0000 0.9644
1 . 0 0 0 00 . 9 8 6 11 . 0 0 0 00 .9760 1.0000 0.9950
0 . 0 0 0 00 . 0 1 4 90 . 0 0 0 00 .2234 1.0000 0.9817
0 . 0 0 0 00 . 0 1 6 90 . 0 0 0 00 .1811 0.0000 0.0005
0 . 0 0 0 00 . 0 1 6 60 . 0 0 0 00 .0336 0.0000 0.0005
0 . 0 0 0 00 . 0 1 5 30 . 0 0 0 00 .0177 0.0000 0.0006
0 . 0 0 0 00 . 0 1 4 90 . 0 0 0 00 .0152 0.0000 0.0005
0.0000 0.0005
0.0000 0.0177
0.0000 0.0180
0.0000 0.0177
0.0000 0.0184
0.0000 0.0218
1.0 indicates positive for DLBCL. DC indicates the actual donor class, with 0.0 being negative. NC gives the network evaluation. The NC cutoff 
throughout this work is: ≥ 0.50 is taken as 1 and <0.50 is taken as 0. * marks the errorsBMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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set of the initial report captured only 7 of the 19 gene set
used for diagnosis and the 148 gene staging set captured
only 2 of the 34 gene set used for prognosis. The 234 gene
subset proposed by Hastie, et al. [4] for prognosis contains
6 of the 34 gene set. There was no overlap with the 13 gene
set identified by Shipp, et al [5] to correlate with their
cured/fatal classes for this disease. At first, it might seem
surprising that the gene subsets identified here do not ap-
pear to be subsets of those identified earlier by Alizadeh et
al. But this surprise is based on a naive intuition. The fact
is that we do not know the level of information redundan-
cy that exists in these large arrays. Apropos of this point,
Alon et al. [6] discarded the 1500 genes indicated by clus-
ter analysis as most discriminatory in their study of colon
cancer and, upon reclustering, found their diagnosis un-
impaired. Likewise, it may be that while the top 10% of
relevant genes might be sufficient for perfect classifica-
tion, so might the next 10%. These sets by definition are
mutually exclusive. By extension, it is not difficult to be-
lieve that some other large gene set might be able to get
75% of the classifications correct with little or no overlap
with those genes in the top 10%.
We have been careful to avoid any claim that the gene sets
extracted in this procedure are the "best" gene sets. Only
in one, highly qualified sense can they be said to be best;
that is in classifying this data set there are no other gene
sets which offer a statistically significant improvement in
classification accuracy. That is not to say that there may
not be other sets which could do as well. Nor is there any
Table 5: Test results of ten networks trained on 19 genes to diagnose 96 donors
DC NC DC NC DC NC
1.000000 0.980997 1.000000 0.951646 1.000000 0.994965
1.000000 0.980266 1.000000 0.949929 1.000000 0.993213
1.000000 0.980299 1.000000 0.954199 1.000000 0.985740
1.000000 0.981223 1.000000 0.953238 1.000000 0.994986
1.000000 0.981232 1.000000 0.672729 1.000000 0.994926
0.000000 0.013813 0.000000 0.013613 0.000000 0.014911
0.000000 0.013742 0.000000 0.062331 0.000000 0.009041
0.000000 0.014832 0.000000 0.014121 0.000000 0.009042
0.000000 0.027310 0.000000 0.013801 0.000000 0.009257
0.000000 0.013980 0.000000 0.014666 0.000000 0.418724
1.000000 0.943310 1.000000 0.961199 1.000000 0.986271
1.000000 0.958110 1.000000 0.976879 1.000000 0.985485
1.000000 0.958936 1.000000 0.960848 1.000000 0.985739
1.000000 0.958939 1.000000 0.978911 1.000000 0.985737
1.000000 0.949335 1.000000 0.977826 1.000000 0.985630
0.000000 0.011627 0.000000 0.017476 0.000000 0.058905
0.000000 0.011927 0.000000 0.031951 0.000000 0.020912
0.000000 0.051333 0.000000 0.016654 0.000000 0.020145
0.000000 0.011654 0.000000 0.018255 0.000000 0.019559
0.000000 0.011726 0.000000 0.016824 0.000000 0.019841
1.000000 0.057607* 1.000000 0.936583 1.000000 0.988447
1.000000 0.980012 1.000000 0.936982 1.000000 0.986334
1.000000 0.979991 1.000000 0.936143 1.000000 0.987346
1.000000 0.964250 1.000000 0.936898 1.000000 0.978961
1.000000 0.979686 1.000000 0.731036 1.000000 0.987996
0.000000 0.015370 0.000000 0.026660 1.000000 0.643879
0.000000 0.020867 0.000000 0.028480 0.000000 0.293788
0.000000 0.015957 0.000000 0.027146 0.000000 0.046603
0.000000 0.015354 0.000000 0.027307 0.000000 0.017312
0.000000 0.015939 0.000000 0.047564 0.000000 0.030104
0.000000 0.860242*
0.000000 0.020264
0.000000 0.020140
0.000000 0.021367
0.000000 0.021137
0.000000 0.020277
DC indicates the actual donor class, with 0.0 being negative. NC gives the network evaluation. The NC cutoff throughout this work is: ≥ 0.50 is 
taken as 1 and <0.50 is taken as 0. * marks the errorsBMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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implication that these genes are seminal in the etiology of
this disease. They may not be necessary but they are suffi-
cient to do this classification. They may not be sufficient
to the classification of a much larger patient set. Forty pa-
tients are unlikely to be fully representative of the general
patient population with this disease. It should be noted,
however, that the same caveats apply to the analysis of
these data by any other method.
There have been a number of additional studies of cancer
using microarray data for either prognostic or diagnostic
purposes. The following listing includes a brief discussion
of 7 of these studies:
(1) Shipp et al.[5] did a study of 58 DLBCL patients and
19 follicular lymphoma patients. They first sought to clas-
sify DLBCL and FL patients. They clustered 6817 genes.
Using their own weighted combination of informative
gene markers, they picked out 30 genes whose expression
levels would be used to do a 2-way classification. They
correctly classified 71/77 patients for a diagnostic accura-
cy of 92%. They then attempted to develop high risk and
low risk groups with respect to 5 year prognosis. They
used several different methods for associating particular
gene clusters with survival outcome: Kaplan Meier analy-
sis, Support Vector Machine, and K-nearest neighbor anal-
ysis. They selected 13 genes as most informative and
achieved the best result with SVM modeling. They did not
explicitly state how many patients initially sorted into the
high risk/low risk groups but other data suggest 17 and 41
respectively. The only way in which these survival proba-
bility plots can be compared to the patient by patient pre-
dictions presented above is to associate low risk with
survival and high risk with non-survival (Please note:this
equation was not made by any of the authors, with the ex-
ception of [3] below, discussing risk groups). If one makes
this association, their best result is 14/58 errors for a 5 yr.
survival accuracy of 76%.
(2) Rosenwald et al. [7] did what they termed a follow-up
study on the original Alizadeh et al. study of DLBCL pa-
tients. However, it was not really a follow-up study be-
cause a different chip was used for the microarray data.
The Alizadeh study identified 2 groups based on an anal-
ysis of weighting the gene cluster groups: germinal center
B cell-like tumors which correlated with low risk and acti-
vated B cell-like tumors which correlated with high risk. If
these groups were made survivors and non-survivors, the
prognosis accuracy would have been 75%. In the follow-
up, the authors found it necessary to introduce a third
group, consisting of patients who did not fit either of the
previous 2 categories. Although lacking the associated
gene profile, this third group had a survival pattern much
like the activated B cell-like group. The authors used Cox
proportional hazards modeling to assign groups on the
basis of the expression of 100 genes. The 5 yr. survival for
the low risk group was 60%, 35% for the activated B cell-
like group, and 39% for the 3rd group. An improved result
was obtained using 16 genes drawn from 4 signature gene
groupings plus a score for BMP6 expression. Kaplan Meier
estimates of survival were determined for 4 quartiles for
which the 5 yr. survival rate was 73%,71%,34%,15%. If
these 4 are collapsed into 2 categories of survivor and
non-survivor, it would produce 62/240 errors for a prog-
nosis accuracy of 74%.
Table 6: 19 genes identified in diagnostic series
19307 Unknown
17250 phospholipaseC
21021 Unknown Hs. 75859
14811 Unknown
16722 CDC-like kinase
12977 similar to retinoblastoma binding protein
18547 CD55
17204 C-rel NF-kB
13828 6-pyruvoyl-tetrahydropterin
17839 tyrosine kinase receptor
21501 cGMP specific binding protein
19337 IP-10
16442 CD14
16877 Thy1
16152 Fc epsilon receptor
19391 osteonectin
19379 cyclin D2
16866 gap junction protein beta1
19376 NK killer cell protein 4BMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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(3) van't Veer et al. [8] did a study of 78 patients with
breast cancer. Starting with 5000 signature genes, they
narrowed down the gene pool to 231 genes by examining
the correlation coefficient of each gene with the prognos-
tic outcome. They then rank ordered these genes and add-
ed them 5 at a time to a one-man-out test of their 77
patients for predicted outcome. This was repeated until an
optimum outcome classification was reached. This oc-
curred at 70 genes. A patient by patient classification
based on the weighting of these 70 genes was able to pro-
duce a survival classification with 13/78 errors for an ac-
curacy of 83%.
(4) Beer et al. [9] used clustering and Cox hazard analysis
to generate a list of 50 genes to be used in Kaplan Meier 5
yr. projections of survival. They had 86 patients with lung
cancer in the study. With 22 patients originally assigned to
the low risk group and 19 to the high risk group, the cor-
responding 5 yr. survival rates were 83% and 40%. If treat-
ed as survival categories this would produce 12/41 errors
for a prognosis classification accuracy of 71%. Although
these authors had complete 5 yr. survival data on 41 of the
patients in the study, they at no point attempted to ana-
lyze this group specifically for direct comparison with
predictions.
(5) Khan et al.[10] used linear neural networks to analyze
microarray data from patients with small round blue-cell
tumors. They wished to classify the 4 subcategories of this
tumor. Principle Component Analysis was used to reduce
2308 genes to 10 components. Neural networks were
trained using 2/3 of a 63 patient pool to train and 1/3 to
test in a fully cross-validated fashion. The groups were
shuffled 1250 times to produce 3750 networks. These net-
works correctly classified all 63 patients in a 4-way classi-
fication. The networks were analyzed for the most
influential inputs to produce a list of 96 genes. New net-
works were calibrated with just these 96 genes; these again
correctly classified the 63 patients and also correctly clas-
sified the 25 patients who had been withheld from the
whole process.
(6) Dehanasekaran et al. [11] did a study of 60 prostate bi-
opsy samples, 24 non-tumorous,14 tumor in situ, 20 met-
astatic tumor. Cluster analysis of microarray data from
nearly 10,000 genes misplaced 2 samples out of 26 for a
diagnostic accuracy of 92%. The authors did not state why
they limited the clustering result to 26 samples when they
had 60. Although they performed additional analyses,
they did not involve using the array data for either diagno-
sis or prognosis.
(7) Golub et al. [12] wished to be able to distinguish acute
myeloid leukemia (AML) from acute lymphoblastic
leukemia (ALL). Starting with the expression of 6817
genes from 38 patients, they did a 2-class clustering. They
then did a neighbor analysis to identify 1100 genes occur-
ring above chance levels which related to the AML/ALL
distinction. They choose an informative subset of 50
genes to weight for class assignment of the patients. They
were able to correctly classify 29/34 patients for a diagnos-
tic accuracy of 85%. They next attempted to use self-or-
ganizing-maps (SOM) for 2 classes in place of the initial
clustering. This produced only 4/38 errors for 89% diag-
nostic accuracy. Drawing a 20 gene predictor from these
SOM classes, they again produced 4/38 errors, maintain-
ing a 89% accuracy. These authors also attempted to use
array data to predict clinical outcome on 15 AML patients
but without success.
The identification of specific genes associated with a par-
ticular biological characteristic such as malignant pheno-
type would be useful in many settings, [1] Precise
classification and staging of tumors is critical for the selec-
tion of the appropriate therapy. At present, classification
is accomplished by morphologic, immunohistochemical,
and limited biological analyses. Neural net analysis in the
form of specific donor profiles could provide a fine struc-
ture analysis of tumors characterizing them by a precise
weighting of the genes, which they express differentially.
At present, only subsets of patients with a given type of tu-
mor respond to therapy. Networks trained to distinguish
responders from non-responders would allow a compari-
son of tumor-expressed genes in responders and non-re-
sponders to find those genes most predictive of response.
Recently we have used neural networks on the data of Per-
ou et al. [12] for classifying breast tumors as hormonally
responsive or non-responsive. Networks that gave a per-
fect classification with 496 genes pointed to a subset of 12
genes. Retraining on these 12 genes produced no error in
classifying 62 tissue samples from their study (unpub-
lished data). We have also analyzed the data of Dha-
nasekaran, et al [11]. Here the original set of 9984 genes
was reduced to 34 genes. Retraining on these 34 genes
gave no errors in a 3-way (normal, early tumor, metastatic
disease) classification of 53 patients (unpublished data).
Given the significant impairment in the quality of life for
many patients undergoing chemotherapy and/or radia-
tion therapy, such prospective information would be ex-
tremely beneficial. [3] T cell and antibody-mediated
immunotherapy may be efficacious approaches for limit-
ing tumor growth in cancer patients. At present there is a
paucity of known tumor rejection antigens that can be tar-
geted. Neural net analysis may identify a panel of tumor-
encoded genes shared by many patients with the same
type of cancer and thereby provide a repertoire of poten-
tially novel tumor rejection antigens. [4] For many pa-
tients with autoimmune disease the target antigen(s) is
unknown. Enhanced identification of cell-type specific
markers of the target organ through neural net profilingBMC Bioinformatics 2003, 4 http://www.biomedcentral.com/1471-2105/4/13
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could identify potential target antigens as candidate mol-
ecules for testing and tolerance induction.
Conclusions
We believe neural networks will be an ideal tool to assim-
ilate the vast amount of information contained in micro-
arrays. The artificial networks presented here were not
selected from a large number of attempts. The networks
described here are the first or second attempts with the
data and format stated; the longest training session lasted
less than 5 minutes. Indeed, the trained neural network
may, in the form of its weight matrix, have the best possi-
ble "understanding" of the very broad statement being
made in the microarray, a view that is accessible with the
differentiation of the network. In this study, that
viewpoint suggested a small subset of genes, which
proved sufficient to give a near-perfect classification in
each of two problems. This approach should be suitable
for any microarray study and, indeed, other global studies
such as 2-D gels and mass-spec data which contain suffi-
cient information for training.
Methods
The data from microarray experiments are stored in
spreadsheet form, representing the positive or negative
level of expression, relative to some control state, of
1000's of genes for two or more experimental conditions.
A short software program is sufficient to translate these
data directly into a binary representation suitable as input
vectors for a neural network. The neural network software
used throughout this study was NeuralWorks Professional
II Plus v.5.3.Neural networks were trained on the corre-
sponding data sets, with a fraction of the data, typically
10%, withheld for testing purposes. All open fields in the
data array were set to zero. The trained networks were then
asked to classify new test data as to donor type. Since the
gene expression levels are read directly from the spread-
sheet, their order and names are provided by the spread-
sheet. Given the large amount of input data, these
networks generally converge to a low error level very
quickly during training, often in a few minutes or less.
Subsequently additional networks were trained with a
simplified input that contained only qualitative informa-
tion in the form of a plus or minus sign to characterize the
expression of each gene in the panel. This reduced the in-
put size to 2 bits per gene, 01 for below the control and 10
for above, or equal to, the control. The output neuron was
trained to output 1.0 for a positive donor and 0.0 for a
negative donor in the diagnostic networks; for the prog-
nostic networks 1.0 indicated a non-survivor and 0.0 a
survivor. The 4026 gene panel network was provided, re-
spectively, 100 or 67 middle-layer neurons for the 3 bit or
2 bit per gene inputs. With a very large number of input
neurons it is possible to overload the middle-layer neu-
rons, effectively always operating them at one extreme
limit or the other; this can have the undesirable effect of
reducing their sigmoid transfer function to a step func-
tion, with the loss of the network's non-linearity. This is
clearly indicated if multiple output values are found to be
exactly identical. Networks were trained to an error level
below 0.05 after which they were tested with previously
unseen data. A possible disadvantage of neural networks,
especially with a large input space and a relatively small
sample number, is overtraining. In overtraining, a net-
work can learn the specifics of each training example as
opposed to finding a global solution for the entire train-
ing set. This behavior is characterized by a degradation in
test scores as training sessions are extended. Although we
saw no evidence of this in this study, we did look to see
how much additional training would be necessary to de-
grade the test results in the case of the initial diagnosis net-
works with 4026 genes. It was not until we doubled the
training iterations dictated by the 0.05 output error cutoff
that we saw some increased test error. At double the nor-
mal training interval, 8 networks were unchanged, but 2
networks showed an increased error of 1. This is sugges-
tive, but not proof, of the onset of overtraining. The net-
works trained on the reduced 34 or 19 gene sets had 6 or
4 middle-layer neurons.
To differentiate a trained network with respect to specific
inputs, a network was trained on the 4026 gene panel
with 2 bits per gene. The 5 positive donors from the test
set were each differentiated, using software that we de-
signed for that purpose [2]. The selected genes were then
compared among the 5 sets, with genes occurring in 3 or
more instances being included in the final subset. This re-
quirement generated a subset of 292 genes from the orig-
inal 4026 genes. Networks were trained on this 292 gene
subset and on two 146 gene subsets, representing every
other gene from the 292 set. All were coded with 3 bits per
gene and employed networks with 25 or 12 middle-layer
neurons, respectively. Other networks were trained on the
292 gene set and the 146 'even' set, coded with 2 bits per
gene for subsequent differentiation.
The differentiation of the large panel networks trained for
prognosis arbitrarily employed more selective criteria (see
text) for subset determination with the result that a single
differentiation reduced the gene set from 4026 genes to 34
genes. Subsequent networks demonstrated that this was a
highly effective selection.
All networks in this study were three-layer back propaga-
tion networks trained with a learning coefficient of 0.3
and a momentum coefficient of 0.4 using the generalized
delta learning rule and the standard sigmoidal transfer
function. The cutoff, in all cases, between positive and
negative scoring was taken to be 0.05 RMS error at the out-
put neuron No network required more than 4 minutesPublish with BioMed Central    and   every 
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training time on a PC at 650 Mh; in the majority of cases,
the network was fully trained in less than a minute. Train-
ing and testing a 10 network round-robin series could
generally be done in less than 20 minutes. Training was
deliberately kept to a minimum to avoid over-training.
The networks represented here were in each case the first
or second attempt result for the given problem. There was
no "data trolling."
Note
1All data not shown can be found at the site http://re-
search.umbc.edu/~moneill/GBMS
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